(TVTX) Travere Therapeutics - Ratings and Ratios

Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company focused on developing and delivering therapies for rare kidney and metabolic disorders. The company’s product portfolio includes FILSPARI (sparsentan), an oral dual-acting endothelin and angiotensin receptor blocker designed to address IgA Nephropathy, a condition causing progressive kidney damage. Additionally, Travere markets Thiola and Thiola EC (tiopronin), treatments for cystinuria, a genetic disorder leading to elevated urinary cystine levels and recurrent kidney stones.

The company’s clinical pipeline includes sparsentan, an investigational therapy with Orphan Drug Designation for focal segmental glomerulosclerosis (FSGS) in the U.S. and Europe, and Pegtibatinase (TVT-058), a novel enzyme replacement candidate for classical homocystinuria, a rare metabolic disorder. Travere collaborates with PharmaKrysto Limited on preclinical activities for cystinuria. Formerly known as Retrophin, Inc., the company rebranded as Travere Therapeutics in November 2020 and is headquartered in San Diego, California.

Ticker Symbol: TVTX Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology

Resistance: 21.1 Support: 20.0 Support: 17.4 Support: 13.4

Average Volume 20d: 1,565,138 Last Price: 20.76 SMA 20: 16.35 SMA 50: 18.54 SMA 200: 16.45 ATR: 1.20

Market Cap: $1,627.19M USD P/E: None P/E Forward: None P/B: 27.54 P/S: 6.98 RoE: None

3-Month Forecast: Based on the technical and fundamental data: - Technical Outlook: The stock is currently consolidating above the 20.0 support level but below the 21.1 resistance. The SMA 20 (16.35) and SMA 50 (18.54) suggest a potential uptrend, while the SMA 200 (16.45) indicates longer-term support. The ATR of 1.20 signals moderate volatility. - Fundamental Outlook: With a market cap of $1.627B and a P/B ratio of 27.54, the stock appears richly valued. The P/S ratio of 6.98 reflects strong revenue multiples. The lack of P/E and RoE data may indicate current losses, but progress in the clinical pipeline could drive sentiment. Forecast: The stock is likely to test the 21.1 resistance level in the near term. If resistance is broken, expect a move toward 22.5. If the 20.0 support fails, the stock may decline to 17.4, with potential further downside to 13.4 if selling pressure intensifies. The ATR suggests price swings of approximately $1.20 per session, making volatility a key factor in the short term.